A Phase 3 interventional study of Rotigotine 1 milligram/24 hours and Rotigotine 2 milligram/24 hours in Restless Legs Syndrome, sponsored by UCB Biopharma SRL. Terminated at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-10-26.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 16th largest by enrollment, is the only one that started in 2018, is one of 10 in phase 3, and was the 18th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2018.
This study's enrollment of 23 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
17 studies in Restless Legs Syndrome by UCB S.A.: none open now, none under way, none of them phase 3. Of 17 finished, 11 (65%) have results posted.
Among the 17 studies in Restless Legs Syndrome by UCB S.A., this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 9 in phase 3, and was the 16th registered.
UCB S.A.’s Restless Legs Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 17 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and tolerability of rotigotine in adolescent subjects with idiopathic RLS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
Drug: Rotigotine 1 milligram/24 hours · Drug: Rotigotine 2 milligram/24 hours
Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine (1 mg/24 h patch + 2 mg/24 patch at the same time), which is the assigned dose level throughout the 12-week Maintenance Period.
Drug: Rotigotine 1 milligram/24 hours · Drug: Rotigotine 2 milligram/24 hours
Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
Drug: Placebo
Drug page: Rotigotine
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).
Also known as: Neupro
Drug page: Rotigotine
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).
Also known as: Neupro
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score
The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe. The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms). A score between 31 and 40, indicates very severe RLS. A score between 21 and 30 indicates severe RLS. A score between 11 and 20 indicates moderate RLS. A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS. A negative change from Baseline indicates improvement.
Time frame: From Baseline to the end of the Maintenance Period (Day 106)
Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period
The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill. The CGI Item 1 was completed during an interview between the participant and the investigator or designee. A negative change from Baseline indicates improvement.
Time frame: From Baseline to the end of the Maintenance Period (Day 106)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
Time frame: From Baseline to Safety Follow-Up (up to Week 20)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals
TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
Time frame: From Baseline to Safety Follow-Up (up to Week 20)
Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period
The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales. The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities. In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied). The change from baseline was derived for each of the subscales and reported in this outcome measure. A negative change from Baseline indicates improvement.
Time frame: From Baseline to the end of the Maintenance Period (Day 106)
The study started to enroll participants in December 2018 and concluded prematurely in July 2022.
| Milestone | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h |
|---|---|---|---|
| Started | 8 | 8 | 7 |
| Completed | 5 | 7 | 6 |
| Not completed | 3 | 1 | 1 |
| Withdrew: Withdrawal by parent/guardian | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe. The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms). A score between 31 and 40, indicates very severe RLS. A score between 21 and 30 indicates severe RLS. A score between 11 and 20 indicates moderate RLS. A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS. A negative change from Baseline indicates improvement.
| score on a scale | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h |
|---|---|---|---|
| Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score | -8.2 ± 6.8 | -14.0 ± 8.2 | -6.4 ± 5.8 |
The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill. The CGI Item 1 was completed during an interview between the participant and the investigator or designee. A negative change from Baseline indicates improvement.
| score on a scale | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h |
|---|---|---|---|
| Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period | -1.0 ± 1.4 | -1.7 ± 1.1 | -0.8 ± 0.8 |
TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
| percentage of participants | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h |
|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 87.5 | 87.5 | 71.4 |
TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
| percentage of participants | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h |
|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals | 12.5 | 0 | 0 |
The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales. The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities. In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied). The change from baseline was derived for each of the subscales and reported in this outcome measure. A negative change from Baseline indicates improvement.
| score on a scale | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h |
|---|---|---|---|
| Satisfaction with sleep | -1.8 ± 4.1 | -4.7 ± 2.3 | -2.0 ± 2.8 |
| Severity: RLS symptoms at falling asleep | -2.8 ± 3.6 | -5.6 ± 1.6 | -2.8 ± 1.8 |
| Severity: RLS symptoms during the night | -1.0 ± 2.5 | -2.9 ± 3.0 | -2.4 ± 2.2 |
| Severity: RLS symptoms during the day - at rest | -1.4 ± 1.3 | -3.6 ± 3.5 | -2.4 ± 2.6 |
| Severity: RLS symptoms during the day-not at rest | -3.8 ± 1.9 | -4.3 ± 3.5 | -0.4 ± 1.1 |
| How tired or sleepy during the day | -3.0 ± 2.8 | -5.6 ± 2.1 | -3.0 ± 1.9 |
Collected over From Baseline to Safety Follow-Up (up to Week 20). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Rotigotine 2 mg/24h | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Rotigotine 3 mg/24h | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Event | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h |
|---|---|---|---|
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/8 | 0/8 | 1/7 |
| Event | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h |
|---|---|---|---|
| Application site erythemaGeneral disorders | 1/8 | 4/8 | 1/7 |
| Upper respiratory tract infectionInfections and infestations | 1/8 | 0/8 | 3/7 |
| Application site pruritusGeneral disorders | 0/8 | 3/8 | 1/7 |
| NauseaGastrointestinal disorders | 1/8 | 2/8 | 0/7 |
| VomitingGastrointestinal disorders | 1/8 | 2/8 | 0/7 |
| Abdominal painGastrointestinal disorders | 2/8 | 0/8 | 0/7 |
| NasopharyngitisInfections and infestations | 2/8 | 0/8 | 0/7 |
| DizzinessNervous system disorders | 2/8 | 0/8 | 1/7 |
| PruritusSkin and subcutaneous tissue disorders | 0/8 | 2/8 | 1/7 |
| Skin irritationSkin and subcutaneous tissue disorders | 0/8 | 2/8 | 0/7 |
The Randomized Set consisted of all participants from the Enrolled Set who have been randomized.
| Age, Continuous(years) | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h | Total |
|---|---|---|---|---|
| Mean | 15.4 ± 1.3 | 16.1 ± 1.1 | 15.6 ± 1.0 | 15.7 ± 1.1 |
| Age, Customized(Participants) | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h | Total |
|---|---|---|---|---|
| Adolescents (12-17 years) | 8 | 8 | 7 | 23 |
| Sex: Female, Male(Participants) | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h | Total |
|---|---|---|---|---|
| Female | 6 | 6 | 2 | 14 |
| Male | 2 | 2 | 5 | 9 |
| Race/Ethnicity, Customized(Participants) | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h | Total |
|---|---|---|---|---|
| American Indian/Alaskan Native | 0 | 1 | 0 | 1 |
| Black | 0 | 0 | 1 | 1 |
| White | 7 | 7 | 6 | 20 |
| Other/Mixed | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | Rotigotine 2 mg/24h | Rotigotine 3 mg/24h | Total |
|---|---|---|---|---|
| Not Hispanic or Latino | 8 | 8 | 7 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · vivli.org
Ran from Dec 2018 to primary completion in Jul 2022, 43 months.
Results were first posted in Oct 2023, 1 year 3 months after primary completion. A results delay was requested in Jul 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine